Opus Genetics CEO granted 483,639 RSUs

Opus Genetics, Inc. Chief Executive Officer and director Magrath George reported an equity award of company common stock.

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Executive Officer and director Magrath George reported an equity award of company common stock. On January 22, 2026, he received 483,639 shares of common stock at a price of $0 per share, described as a grant of restricted stock units. After this grant, he beneficially owned 1,775,293 shares of Opus Genetics common stock in direct ownership.

The restricted stock units vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, and vesting is conditioned on his continuing service.

Insider Trade Summary

Grant/Award: 483,639 shares

Grant/Award 1 txn

Insider Magrath George

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	483,639	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,775,293 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for Magrath George?

Opus Genetics reported that Chief Executive Officer and director Magrath George received an award related to 483,639 shares of common stock on January 22, 2026, recorded at $0 per share as a grant of restricted stock units.

How many Opus Genetics (IRD) shares does Magrath George hold after this Form 4 transaction?

Following the reported grant, Magrath George beneficially owned 1,775,293 shares of Opus Genetics common stock in direct ownership.

What are the vesting terms of the restricted stock units granted to the Opus Genetics CEO?

The filing states that the grant represents restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, subject to his continuing service.

Was the insider transaction by Magrath George a purchase or a grant of Opus Genetics (IRD) stock?

The transaction was reported with code A and described in the footnote as a grant of restricted stock units, not an open-market purchase or sale.

Does Magrath George hold the Opus Genetics (IRD) shares directly or indirectly after this grant?

The Form 4 lists the 1,775,293 shares of Opus Genetics common stock as held with direct (D) ownership, with no nature of indirect beneficial ownership specified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 07:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magrath George

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		483,639(1)	A	$0	1,775,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

	/s/ Amy Rabourn, by Power of Attorney	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.